Sign in
WithdrawnPhase 2

A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease

Key facts

Who runs it
The University of Texas Health Science Center, Houston
Trial code
Status
Withdrawn
Phase
Phase 2
Started
1 Dec 2023
Ended
1 Dec 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • PRIM-DJ2727
  • Placebo
Record updated
14 May 2024
Why it stopped
lack of funds

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • ≥ 18 years of age
  • For sexually active male and female subjects of childbearing potential, agree to use an effective method of birth control during the study
  • For female subjects of childbearing potential, a negative urine Qualitative HCG pregnancy test at enrollment and on the Week 1, Day 1 of the Treatment prior to administration of study drug
  • Willing and able to sign an informed consent form and attend study assessments and follow up visits
  • A documented diagnosis of NAFLD without cirrhosis based on imaging or clinical judgment of a gastroenterologist or hepatologist
  • History of diabetes mellitus
  • Has an attending physician who will provide non-transplant care for the subject
  • Agrees to maintain a stable regimen including weight loss, exercise, medications to control lipids and glucose, and vitamin E therapy if already prescribed, during participation in the study

Who cannot take part

  • Receipt of systemic non-topical antibiotic therapy within 14 days of treatment day 1
  • History of use of an investigational drug within 90 days prior to the screening visit
  • Compromised immune system (e.g. primary immune disorders or clinical immunosuppression due to a medical condition or medication e.g. taking oral prednisone >20 mg a day or prednisone-equivalent)
  • Positive results for active HIV, Hepatitis B, or Hepatitis C infections
  • Current history for active states of Inflammatory bowel disease, Irritable bowel syndrome, microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy, gastrointestinal fistulae or strictures
  • History of significant uncontrolled systemic disease that in the opinion of the study investigator could interfere with study participation and/or objectives
  • Unable to take multiple capsules orally
  • Alcohol consumption of greater than an average of one drink per day for women and two drinks per day for men
  • Hemochromatosis
  • Hepatic encephalopathy
  • Life expectancy of < 1 year
  • In the opinion of investigator, subject for any reason, should be excluded from the study

About the trial

What the trial wants to find out

Potential subjects with non-alcoholic fatty liver disease (NAFLD) will be identified by gastroenterologists (study investigators). Twelve eligible subjects with NAFLD will be randomly assigned to receive either active fecal microbiota transplantation in orally administered capsules or Placebo capsules and dosed twice weekly for 12 weeks. .

The 2 groups in the trial

  • Active groupTreatment being tested

    Patients with NAFLD will receive orally fecal microbiota capsules from healthy donors

    Treatment: PRIM-DJ2727

  • Placebo groupPlacebo, for comparison

    Placebo capsules will be identical to the active capsules, but not contain intestinal bacteria

    Treatment: Placebo

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Nonalcoholic Fatty Liver Disease (NAFLD)
Record updated
14 May 2024